|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400087625 |
|
最近更新日期: Date of Last Refreshed on: |
2024-07-31 14:29:04 |
|
注册时间: Date of Registration: |
2024-07-31 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
结核病潜伏感染者的转归及生物标志物研究 |
|
Public title: |
Study on the prognosis and biomarkers of latent tuberculosis infection |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
结核病潜伏感染者的转归及生物标志物研究 |
|
Scientific title: |
Study on the prognosis and biomarkers of latent tuberculosis infection |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
丁振涛 |
研究负责人: |
丁振涛; 刘海清 |
|
Applicant: |
Zhentao Ding |
Study leader: |
Zhentao Ding; Haiqing Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 189 0968 8859 |
研究负责人电话: Study leader's telephone: |
+86 189 0968 8859 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
530172308@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
530172308@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
安徽省阜阳市颍州区阜南路21号 |
研究负责人通讯地址: |
安徽省阜阳市颍州区阜南路21号; 安徽省阜阳市颍河西路1088号 |
|
Applicant address: |
No. 21, Funan Road, Yingzhou District, Fuyang, Anhui Province |
Study leader's address: |
No. 21, Funan Road, Yingzhou District, Fuyang, Anhui Province; 1088 yinghe West Road, Fuyang, Anhui Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
阜阳市疾病预防控制中心 |
||
|
Applicant's institution: |
Fuyang Centers for Disease Control and prevention |
||
|
研究负责人所在单位: |
阜阳市疾病预防控制中心; 阜阳市第二人民医院 |
||
|
Affiliation of the Leader: |
Fuyang Centers for Disease Control and prevention; Fuyang Second People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
20240624028 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
阜阳市第二人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Fuyang Second People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-24 00:00:00 |
||
|
伦理委员会联系人: |
刘军 |
||
|
Contact Name of the ethic committee: |
Jun Liu |
||
|
伦理委员会联系地址: |
安徽省阜阳市颍河西路1088号 |
||
|
Contact Address of the ethic committee: |
1088 yinghe West Road, Fuyang, Anhui Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 558 256 3957 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
阜阳市第二人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Fuyang Second People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
安徽省阜阳市颍河西路1088号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1088 yinghe West Road, Fuyang, Anhui Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
安徽省卫生健康委 |
||||||||||||||||||||||
|
Source(s) of funding: |
Health Commission of Anhui Province |
||||||||||||||||||||||
|
Target disease: |
Tuberculosis |
||||||||||||||||||||||
|
Target disease code: |
L2-1B1 |
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
一方面分析本地预防性治疗依从性,观察治疗过程中不良反应以及监测活动性结核发生情况;另一方面基于代谢组学分析方法,挖掘潜伏感染人群进展为活动性肺结核的生物标志物,锁定预防性治疗受益较大人群,从而为精准预防性治疗潜伏感染人群提供参考依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
On the one hand, to analyze the compliance of local preventive treatment, observe the adverse reaction during treatment and monitor the occurrence of active tuberculosis, on the other hand, based on the metabolomics analysis method, to tap the latent infected population to develop into the biomarkers of active pulmonary tuberculosis, and to lock the population who benefit from the preventive treatment, so as to provide reference for the accurate preventive treatment of the latent infected population. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.PPD阳性(排除卡介苗接种反应)或IGRA阳性或EC阳性; 2.无活动性结核的临床症状(如发热、咳嗽、咳痰、咯血、乏力、盗汗、胸痛、体重下降、食欲不振等); 3.影像学未发现结核病灶; 4.痰细菌学阴性。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. PPD positive (excluding BCG vaccination) or IGRA positive or EC positive; 2. No symptoms of active tuberculosis (fever, cough, expectoration, hemoptysis, fatigue, night sweats, chest pain, weight loss, loss of appetite, etc.) ; 3. No focus of tuberculosis was found on imaging; 4. Sputum was bacteriologically negative. |
||||||||||||||||||||||
|
排除标准: |
1.排除1岁以内的婴幼儿; 2.孕妇及哺乳期或2年计划妊娠的妇女; 3.排除人类免疫缺陷病毒感染检查表现为阳性; 4.肝、肾功能异常或损伤患者; 5.患有癫痫或其他精神疾病者; 6.嗜酒、吸毒等不良嗜好者; 7.不愿意提供个人信息或临床样本不能利用的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Exclude infants and young children under 1 year of age; 2. Pregnant and lactating women or women planning a 2-year pregnancy; 3. Human immunodeficiency virus (HIV) infection was excluded; 4. Patients with abnormal or impaired liver or renal function; 5. People with epilepsy or other mental illness; 6. An alcoholic, drug addict, etc.; 7. Patients who are unwilling to provide personal information or whose clinical samples can not be utilized. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-01 00:00:00至 To 2026-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-08-01 00:00:00 至 To 2025-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not public |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
人口数据来自于国家及地方统计部门;结核病病例数来自于结核病管理信息系统;诊疗数据来自于医院病例系统;前瞻性随访数据采用病例记录表进行电子采集,并由数据管理员进行信息化管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Population data comes from national and local statistical departments; The number of tuberculosis cases comes from tuberculosis management information system; The diagnosis and treatment data comes from the hospital's case system; Prospective follow-up data is electronically collected using case record forms and managed by data administrators through information technology. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |